Are you familiar with the proposed draft guidance we submitted in mid-May for FDA consideration? It’s titled Testing of Adeno-Associated Viral (AAV) Vector-Based Human Gene Therapy Products for Empty Capsids During Product Manufacture. You can read the press release here or jump directly to the complete document here. If you’d like to contact us in regards to this draft guidance, please email  aavguidancedoc@darkhorseconsultinggroup.com.

accelerating

cell & gene therapies

through unmatched expertise

Services

We apply pharmaceutical industry best practices to the unique challenges of the Cell and Gene Therapy (C&GT) field. Our team can help you with a wide range of needs, spanning from high level corporate strategy development to detailed technical implementation.

We have a dozen commonly-requested services, listed below.

During 2020, we released 20 case studies to provide concrete examples of how our expertise can support your business. In 2021 we added two additional case studies to the bank. Both of them (Remediation of CRL issues for BLA resubmission, and Embedded early for de novo support) are applicable to six of our twelve service areas. See all case studies in one place here.

  • Quantitative modeling
  • CMO selection
  • Technology transfer
  • Facility design
  • Failure analysis

  • Comparability studies
  • Process codification
  • Process evaluation 
  • Process dev planning


  • Method development
  • Specification setting
  • Method transfer
  • Qualification & validation
  • Remediation
  • Comparability testing
  • Capacity planning
  • Cost-of-goods analysis
  • Build vs. Buy analytics



  • QMS design and strategy
  • QMS gap assessment
  • Document authoring, review, and revision
  • Supplier oversight
  • Audits (see flyer below)
  • URS development
  • Landscape scan & gap analysis
  • Custom device design
  • Contract manufacturing management
  • DHF & DMF development
  • Regulatory strategy
  • Technical writing/editing
  • Gap analyses
  • Meeting assistance
  • Preclinical strategy
  • Study design and oversight
  • Vendor selection
  • Technical writing
  • Critical path identification
  • Project management
  • Strategic project planning
  • Stage-gating
  • Needs assessment
  • Voice of customer surveys
  • Marketing strategy



  • Strategic portfolio
    assessment & analysis
  • Landscape analysis and competitive intelligence
  • IP due diligence
  • IP strategy
  • Due diligence
  • Message optimization




Ready for our Quarter Horse, Issue 6? (If you're an email subscriber, you might have seen this come through two days ago; this can serve as a reminder if you haven't read it yet!) Here you go: https://bit.ly/DHCQuarterHorseIssue6
In this quarterly newsletter you'll read more about (1/2)

We're finishing out our Pride month quotes w/ some thoughts from COO/MP Katy Spink regarding the work still to be done. Happy Pride, everyone! Our logo may be back to our DHC green tomorrow, but we'll keep the rainbow in our hearts & intentions year-round. 🌈❤️🧡💛💚💙💜🤎🖤🏳️‍⚧️

2Q '22 new-hire round-up, here we come! This quarter we added an additional amazing five full-time Horses: one Principal (Brent Morse, specializing in potency assay dev, analytical comparability, tech transfers, & x-functional leadership), two Senior Consultants (1/3)

This is so great, @endpts: love it! https://endpts.com/15-leaders-giving-voice-and-visibility-to-the-lgbtq-community-in-biopharma/

We use cookies to help give you the best experience on our website. By continuing you agree to our use of cookies.